EUCTR2011-003943-23-DE进行中（未招募）不适用
Prospective, randomized, partly blinded, in part placebo-controlled, multicenter, dose-finding trial exploring safety, tolerability and efficacy of a topical resiquimod gel in patients with multiple actinic keratosis lesions
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 208
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Signed informed consent
- •Male or nonpregnant, nonlactating female, =18 years. For women of childbearing potential the use of highly effective methods of birth control (precautions to prevent pregnancy) is mandatory. Highly effective methods of birth control are defined as those, alone or in combination, which result in a low failure rate (i.e. less than 1 % per year) when used consistently and correctly - such as implants, injectables, combined oral contraceptives, some IUDs, sexual abstinence or vasectomised partner. In this trial women of childbearing potential are instructed to use oral contraceptives or IUDs in combination with a barrier device (e.g. condom).
- •A minimum of 2 clinically diagnosed AK-lesions within a 25 cm2 contiguous treatment area (balding scalp, forehead, face). One AK-lesion must have a diameter of at least 6 mm (indicator lesion).The patient may have been treated in the past for AK-lesions. But for the existing AK-lesions the restrictions for treatments before the start of the trial must be observed (see below exclusion criteria).
- •Free of other significant findings in the treatment field that could impair examination of the treatment or surrounding area (defined as the area within a 5 cm margin of the treatment area
- •in all directions).
- •Willing and able to participate in the trial as an outpatient and comply with all trial requirements.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Evidence of unstable or uncontrolled clinically significant medical conditions as determined by the investigator (e.g., cardiovascular, immunosuppressive, hematologic, hepatic, neurologic, renal, endocrine, collagen-vascular, gastrointestinal abnormalities or diseases).
- •Evidence of an active infection.
- •Evidence of immunosuppression or systemic cancer.
- •Known autoimmune disorder (especially psoriasis), impaired immune system (e.g. HIV), known thyroid abnormalities, known depression.
- •Dermatological disease or condition in the treatment or surrounding area that might be exacerbated by treatment with resiquimod gel or may impair trial assessments (e.g., rosacea, atopic dermatitis, eczema) as assessed by the investigator.
- •Current alcohol abuse or chemical dependency as assessed by the investigator.
- •Participation in another clinical trial within one month of trial entry.
- •Known allergy or hypersensitivity to any of the trial gel ingredients.
- •Pretreatments for the existing AK-lesions are restricted before the start of the trial, in the sense that different periods of grace must be observed:
- •Local/topical treatments in the treatment area
- •Dermabrasion, chemical peeling, laser treatment, cryotherapy or surgery within 6 weeks of trial entry
- •Imiquimod, diclofenac, 5-Fluorouracil (5-FU), topical corticosteroids, topical retinoids, treatment of the head with ultraviolet B (UVB) or photodynamic treatment (PDT) within 6
- •weeks of trial entry
- •Systemic treatments
- •High-dose vitamin A (>15’000 units per day) within 2 weeks of trial entry
- •Interferon/ interferon-inducers, immunosuppressors, immunomodulatory medicinal products, systemic (>10 mg/day) or high-dosed inhaled (>1600 µg/day) corticosteroids within 4 weeks of trial entry
- •Chemotherapy or systemic retinoids within 6 months of trial entry.
研究者
相似试验
进行中（未招募）
不适用
A partially randomized, partially double-blind, placebo-controlled Phase II non-inferiority study to evaluate immunogenicity and safety of one and two doses of MVA-BN (IMVAMUNE™) smallpox vaccine in 18-55 year old healthy subjectsHealthy subjects - prevention of smallpox infectionMedDRA version: 8.0Level: PTClassification code 10041197EUCTR2005-001781-14-DEBavarian Nordic A/S800
进行中（未招募）
不适用
A partially blinded, prospective, randomized multicenter study evaluating efficacy, safety and tolerability of oral sotrastaurin plus standard or reduced exposure tacrolimus vs. myfortic plus tacrolimus in de novo renal transplant recipients - A2214Renal allograft transplantationMedDRA version: 12.0Level: LLTClassification code 10066543Term: Acute allograft rejectionEUCTR2009-015456-14-HUovartis Pharma Services AG300
进行中（未招募）
1 期
A partially blinded, prospective, randomized multicenter study evaluating efficacy, safety and tolerability of oral sotrastaurin plus standard or reduced exposure tacrolimus vs. myfortic plus tacrolimus in de novo renal transplant recipients - A2214Renal allograft transplantationMedDRA version: 14.1Level: LLTClassification code 10066543Term: Acute allograft rejectionSystem Organ Class: 10021428 - Immune system disordersEUCTR2009-015456-14-GBovartis Pharma Services AG
进行中（未招募）
不适用
A partially blinded, prospective, randomized multicenter study evaluating efficacy, safety and tolerability of oral sotrastaurin plus standard or reduced exposure tacrolimus vs. myfortic plus tacrolimus in de novo renal transplant recipients - A2214Renal allograft transplantationMedDRA version: 12.0Level: LLTClassification code 10066543Term: Acute allograft rejectionEUCTR2009-015456-14-NLovartis Pharma Services AG300
进行中（未招募）
1 期
A partially blinded, prospective, randomized multicenter study evaluating efficacy, safety and tolerability of oral sotrastaurin plus standard or reduced exposure tacrolimus vs. myfortic plus tacrolimus in de novo renal transplant recipients - A2214Renal allograft transplantationMedDRA version: 14.1Level: LLTClassification code 10066543Term: Acute allograft rejectionSystem Organ Class: 10021428 - Immune system disordersEUCTR2009-015456-14-BEovartis Pharma Services AG300